Prevention & care

Hepatitis C: bloodborne infection, antibody versus RNA, cure, reinfection, and liver follow-up

6 sources · Latest source check 2026-10-13 UTC

On this page

Hepatitis C is a liver infection caused by hepatitis C virus, or HCV. It is mainly bloodborne and can be acute or chronic. Many people have no symptoms, so a person’s wellbeing cannot establish whether the virus is present. It is distinct from hepatitis B despite the shared word “hepatitis.”[1]

Exposure, current infection and damage need different assessment

Exposure, current infection and damage need different assessment
Measure	What it addresses
HCV antibodies	Evidence of past or current exposure; a reactive result alone does not establish current infection.[2]
HCV RNA	Detectable viral genetic material supports current infection.[2]
Liver assessment	Blood tests and other methods evaluate damage separately from the antibody result.[4]

Blood exposure and casual contact are different

Shared injection equipment, contaminated sharp instruments and some healthcare exposures can transmit HCV; blood can be present in amounts too small to see. Sexual transmission is possible but less common and depends on the exposure context. CDC does not identify hugging, sharing utensils, food or water as transmission routes.[3]

A positive antibody result is the start of interpretation

CDC recommends antibody testing followed by RNA testing when reactive, ideally without requiring a second visit just to collect another sample. A positive antibody result can reflect current infection, a past resolved infection or a false-positive result. Recent exposure can also precede detectable antibodies, so a negative result has a timing limitation.[2]

Screening addresses an illness that can remain unnoticed

NHS describes fatigue or other vague symptoms alongside long symptom-free periods. Chronic infection can damage the liver before a person realizes it. Screening recommendations vary by jurisdiction and exposure history; an absence of symptoms is not a substitute for testing when a guideline or clinician identifies a reason.[5]

Clearing the virus and repairing the liver are separate goals

WHO describes cure rates above 95% with modern direct-acting antivirals. That population summary is not a guarantee for every individual.[1]

Liver disease, other conditions and drug interactions affect treatment planning. Supplements require assessment rather than replacing evidence-based antiviral care.[4]

NIDDK emphasizes assessing liver damage and other infections before treatment. People with cirrhosis can still require monitoring for complications after infection is treated. A successful virus result therefore should not be assumed to erase every liver-health question. Supplements and other medicines can cause harm or interact with treatment.[4]

Cure does not act as a vaccine

Someone who previously had hepatitis C can be infected again. Sterile equipment, safer injection services and preventing blood exposure remain relevant after cure. Vaccination against hepatitis A or B can address those separate infections, but neither is a vaccine against HCV.[3][4]

Access and follow-up are part of the outcome

NHS care includes testing, specialist assessment and treatment rather than relying on symptoms alone. Current drug availability, financing and individual eligibility need local verification. Symptoms suggesting liver complications need assessment; a reader explainer cannot decide the meaning of an abnormal result or choose a specific antiviral.[5]

Cure is confirmed after therapy, rather than by a better symptom

The AASLD/IDSA guidance uses undetectable or nonquantifiable HCV RNA at least twelve weeks after treatment to define sustained virologic response, consistent with virologic cure. Feeling well or having a normal liver-enzyme result is a different finding. The timing and test matter because completion of tablets alone does not document the follow-up outcome.[6]

Evidence & uncertainty

Modern direct-acting antivirals cure most infections, but a cure does not confer immunity to another exposure or automatically reverse established liver damage. An antibody result records a different question from an RNA test. There is no effective hepatitis C vaccine in the checked official guidance.[1][2][4]

Selected-source overview · Independent review pending

Published questions

Are hepatitis B and C the same infection?

Selected-source overview · Independent review pending. Read the evidence context.

They are caused by different viruses and have different prevention and treatment pathways.[1]

Evidence behind this answer

Hepatitis C
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Definition, cure, vaccine status and clinical course